The following presentations will include discussion of commercial products/services:
EP05.79, EP07.24, EP17.75, EP18.07, EP01.01, EP02.03, EP02.11, EP05.09, EP05.83, EP08.12, EP08.34, EP08.65, EP08.68, EP08.69, EP09.21, EP09.26, EP09.36, EP09.45, EP09.49, EP09.57, EP10.30, EP10.46, EP11.01, EP12.01, EP12.13, EP12.20, EP14.17, EP14.22, EP15.11, EP15.23, EP16.09, EP17.29, EP17.36, EP17.42, EP18.16, EP18.17, EP19.08, EP19.14, OC02.02, OC03.03, OC04.04, OC05.02, OC13.01, OC13.08, C14.05, OC15.05, OC19.04, OC21.03, OP01.04, OP01.09, OP04.02, OP07.06, OP08.04, OP09.08,
 

The following presentations will include discussion of investigative or off label uses of products:

EP06.10, EP09.34, EP10.24, EP10.41, EP16.51, EP08.16, EP08.34, EP08.68, EP09.26, OP09.43, EP10.09, EP16.09, EP17.08, EP17.29, EP17.42, OC07.03, OP08.06,  

The following presentations will include discussion of clinical studies:

EP06.10, EP07.27, EP10.24, EP11.14, EP11.25, EP11.37, EP13.28, EP02.04, EP02.11, EP04.15, EP05.17, EP05.82, EP05.83, EP06.01, EP06.04, EP06.07, EP07.01, EP07.07, EP07.17, EP08.05, EP08.08, EP08.13, EP08.16, EP08.19, EP08.21, EP08.35, EP08.39, EP08.40, EP08.42, EP08.45, EP08.50, EP08.52, EP08.55, EP08.60, EP08.61, EP08.64, EP08.65, EP09.03, EP09.07, EP09.13, EP09.16, EP09.26, EP09.43, EP09.44, EP10.03, EP10.09, EP10.30, EP10.39, EP10.40, EP10.46, EP10.52, EP11.08, EP11.09, EP12.11, EP12.26, EP13.04, EP13.21, EP14.03, EP14.09, EP14.10, EP14.39, EP15.09, EP15.27, EP16.09, EP16.28, EP16.56, EP16.66, EP16.68, EP16.74, EP16.76, EP16.79, EP17.03, EP17.08, EP17.21, EP17.27, EP17.29, EP17.30, EP17.32, EP17.34, EP17.46, EP17.66, EP17.68, EP17.80, EP18.03, EP18.05, EP18.10, EP19.14, OC02.01, OC02.02, OC02.04, OC02.08, OC04.03, OC04.04, OC05.05, OC06.04, OC06.05, OC07.02, OC07.03, OC07.05, OC07.08, OC08.01, OC08.02, OC10.02, OC11.01, OC11.02, OC11.04, OC11.05, OC12.02, OC12.03, OC12.04, OC13.02, OC13.07, OC14.02, OC14.04, OC14.05, OC15.01, OC15.02, OC15.04, OC15.05, OC16.02, OC16.03, OC17.01, OC17.02, OC17.04, OC17.06, OC18.04, OC18.05, OC18.06, OC18.07, C20.07,  OC21.01, OC21.02, OC21.05, OP01.04, OP01.07, OP01.08, OP01.09, OP06.05, OP07.08, OP08.01, OP09.04, OP09.06, OP10.02, OP11.05,

The following presentations will include discussion of financial studies:

EP18.07, EP05.83, EP06.07, EP08.14, EP08.16, EP08.65, EP09.26, EP09.43, EP09.45, EP11.01, EP14.06, EP16.09, EP17.03, EP17.08, EP17.10, EP17.29, EP17.46, EP18.03, EP19.08, OC04.04, OC07.05, OC13.01, OC17.01, OC21.01, OC21.02, OC21.03, OC21.05, OP04.02, OP06.05, OP07.06, OP09.04, OP09.07,

The following speaker declarations have been received:

 

  • Gregor  Kasprian: Philips MRI software to optimize MR images: SmartSpeed
  • Roberto Albinagorta: Demo live with Mindray machines
  • Liona Poon: Ultrasound machines, Data of clinical studies will be presented
  • Aris Papageorghiou: My presentation includes images and videos from ultrasound systems by GE and Samsung, I am a paid consultant for GE healthcare, Limitations of any data will be discussed in the studies
  • Jerome  Cornette: Only if a lecture/Poster is accepted on Graphic Flow. With GE Health Care, research funding for research on Graphic Flow in fetal congenital heart disease.
  • Yves Ville: AI / Sonio AI , Sonio AI , Head of SAB
  • Amarnath Bhide: I will include the test platform used for my work on placental biomarkers.                                                                                                                                       
  • Tom Bourne: Research support from Illumina and Abbott Honoraria from Samsung Healthcare for speaking or chairing CMO and Board member of Gynaia Inc., I am not sure what studies I will discuss this length of the prior to the meeting - but the pros and cons will be discussed
  • Dirk Timmerman: Maybe I will mention Gynaia that provides the IOTA ADNEX model as an app, Founder of Gynaia.com, only peer reviewed published studies
  • Mishella Perez: GE Healthcare
  • Asma Khalil: Advisory role to ultrasound and AI companies
  • Helena Williams: We have had a research service agreement between KU Leuven and general electric healthcare for research and will disclose research undertaken in the context of this project.
  • Waldo Sepulveda: I will receive a fee for my participation in an event organized by Sonoscape
  • Karina Krajden Haratz: research project with GE
  • Jan Deprest: Advisor to VITARA, recipient of instruments of Karl Storz for experimental fetal surgery (in animals). will be discussed during presentation
  • Elisabeth Epstein: We are running clinical trials implementing AI-driven diagnostic support for gynecological ultrasound in collaboration with GE Healthcare and Intelligyn
  • Ritsuko Pooh:  serves as the CEO of Ritz Medical Co., Ltd., and a medical adviser to Japan Genetic Medicine Co.Ltd and is a shareholder
  • Reem Abu-Rustum: Our ultrasound unit at UF is a GE Luminary Site.
  • Tullio Ghi: scientific collaboration with Samsung
  • Anita Moon-Grady: Some discussion of currently active clinical trials may involve devices. will disclose as appropriate. I expect to discuss only peer-reviewed, published clinical research results and will discuss data limitations as appropriate
  • Yinka Oyelese: I may discuss laser for vasa previa briefly. I will discuss limitations of data.
  • Roberto Romero: Vaginal progesterone may be off-label in some countries. I will disclose limitations of data in my presentation.
  • Sue Walker: Published data will be presented
  • Steven R. Goldstein: All data will be from peer reviewed published articles.
  • Jen Barcroft: I will highlight the limitations of the data.
  • Lorraine Dugoff: May provide clinical studies to support clinical recommendations. Will all be non-biased and evidence-based.
  • Mary Norton: I will discuss some in utero clinical trials, including disclosures on limitations of data.
  • Davor Jurkovic: Limitations will be discussed
  • Chris Kyriacou: Ongoing clinical studies are always discussed in this forum. This will be declared
  • Magda Sanz Cortez: I will adhere to CME standards 
  • Simon Meagher: Studies only accessed via PUB MEd online journals etc
  • Daniel Rolnik: Results of clinical research will be discussed, and limitations will be acknowledged.
  • Anita Moon-Grady: I expect to discuss only peer-reviewed, published clinical research results and will discuss data limitations as appropriate
  • Tina Tellum: Limitations will be provided
  • Basky Thilaganathan: The limitations of the presented studies will be discussed during the presentation
  • Mar Gil: Limitations of any study discussed during my presentation will be included within the allocated time
  • Nina Cooper: Will discuss peer reviewed studies
  • Alessandra Familiari: Discussion over the results of RCT on timing of the third trimester scan
  • Shabnam Bobdiwala: all will be referenced in the talks and are studies published in peer-reviewed journals
  • Vincenzo Berghella: RCTs

Share